Suppr
超能文献

A learning experience from price negotiations for vaccines.

作者信息

Teerawattananon Yot, Tritasavit Nattha

机构信息

Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.

出版信息

Vaccine. 2015 May 7;33 Suppl 1:A11-2. doi: 10.1016/j.vaccine.2014.12.050.

DOI:10.1016/j.vaccine.2014.12.050

PMID:25919150

Abstract

摘要

相似文献

A learning experience from price negotiations for vaccines.

Vaccine. 2015 May 7;33 Suppl 1:A11-2. doi: 10.1016/j.vaccine.2014.12.050.

Global harmonisation in vaccine price.

Lancet Infect Dis. 2015 Mar;15(3):249. doi: 10.1016/S1473-3099(15)70067-8.

First countries to be recipients of GAVI funds.

Bull World Health Organ. 2000;78(12):1477-8.

Immunizing the world.

Newsweek. 2000 Dec;136(26A):72-3.

Vaccines at what price?

Vaccine. 2014 Feb 19;32(9):1029-30. doi: 10.1016/j.vaccine.2013.12.066. Epub 2014 Jan 9.

Tiered pricing of vaccines: a win-win-win situation, not a subsidy.

Lancet Infect Dis. 2005 Jan;5(1):58-63. doi: 10.1016/S1473-3099(04)01255-1.

Progress report on the National Immunization Strategy.

CMAJ. 2007 Jun 19;176(13):1811-3. doi: 10.1503/cmaj.070686.

The U.S. vaccine supply.

N Engl J Med. 2005 Mar 10;352(10):1046-7; author reply 1046-7. doi: 10.1056/NEJM200503103521020.

Costs of vaccine programs across 94 low- and middle-income countries.

Vaccine. 2015 May 7;33 Suppl 1:A99-108. doi: 10.1016/j.vaccine.2014.12.037.

What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?

Vaccine. 2015 May 7;33 Suppl 1:A93-8. doi: 10.1016/j.vaccine.2014.12.076.

引用本文的文献

Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.

Nat Rev Nephrol. 2025 Sep 11. doi: 10.1038/s41581-025-01000-w.

Advancing evidence-based decision-making in Bhutan: development of a health technology assessment framework.

Lancet Reg Health Southeast Asia. 2024 Oct 18;30:100489. doi: 10.1016/j.lansea.2024.100489. eCollection 2024 Nov.

Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.

Appl Health Econ Health Policy. 2024 Nov;22(6):797-804. doi: 10.1007/s40258-024-00900-5. Epub 2024 Jul 12.

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.

BMC Public Health. 2022 Dec 16;22(1):2363. doi: 10.1186/s12889-022-14525-7.

Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.

Global Health. 2022 Mar 18;18(1):33. doi: 10.1186/s12992-022-00822-8.

Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.

Appl Health Econ Health Policy. 2021 Jul;19(4):463-472. doi: 10.1007/s40258-021-00661-5. Epub 2021 Jul 8.

Economic evaluation of rotavirus vaccination in children of Bhutan.

Vaccine. 2020 Jul 6;38(32):5049-5059. doi: 10.1016/j.vaccine.2020.05.035. Epub 2020 Jun 7.

A review of promoting access to medicines in China - problems and recommendations.

BMC Health Serv Res. 2018 Feb 20;18(1):125. doi: 10.1186/s12913-018-2875-6.

How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.

Value Health. 2016 Dec;19(8):913-920. doi: 10.1016/j.jval.2016.04.014.

Essential medicines for universal health coverage.

Lancet. 2017 Jan 28;389(10067):403-476. doi: 10.1016/S0140-6736(16)31599-9. Epub 2016 Nov 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

A learning experience from price negotiations for vaccines.

Vaccine. 2015 May 7;33 Suppl 1:A11-2. doi: 10.1016/j.vaccine.2014.12.050.

Global harmonisation in vaccine price.

Lancet Infect Dis. 2015 Mar;15(3):249. doi: 10.1016/S1473-3099(15)70067-8.

First countries to be recipients of GAVI funds.

Bull World Health Organ. 2000;78(12):1477-8.

Immunizing the world.

Newsweek. 2000 Dec;136(26A):72-3.

Vaccines at what price?

Vaccine. 2014 Feb 19;32(9):1029-30. doi: 10.1016/j.vaccine.2013.12.066. Epub 2014 Jan 9.

Tiered pricing of vaccines: a win-win-win situation, not a subsidy.

Lancet Infect Dis. 2005 Jan;5(1):58-63. doi: 10.1016/S1473-3099(04)01255-1.

Progress report on the National Immunization Strategy.

CMAJ. 2007 Jun 19;176(13):1811-3. doi: 10.1503/cmaj.070686.

The U.S. vaccine supply.

N Engl J Med. 2005 Mar 10;352(10):1046-7; author reply 1046-7. doi: 10.1056/NEJM200503103521020.

Costs of vaccine programs across 94 low- and middle-income countries.

Vaccine. 2015 May 7;33 Suppl 1:A99-108. doi: 10.1016/j.vaccine.2014.12.037.

What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?

Vaccine. 2015 May 7;33 Suppl 1:A93-8. doi: 10.1016/j.vaccine.2014.12.076.

引用本文的文献

Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.

Nat Rev Nephrol. 2025 Sep 11. doi: 10.1038/s41581-025-01000-w.

Advancing evidence-based decision-making in Bhutan: development of a health technology assessment framework.

Lancet Reg Health Southeast Asia. 2024 Oct 18;30:100489. doi: 10.1016/j.lansea.2024.100489. eCollection 2024 Nov.

Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.

Appl Health Econ Health Policy. 2024 Nov;22(6):797-804. doi: 10.1007/s40258-024-00900-5. Epub 2024 Jul 12.

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.

BMC Public Health. 2022 Dec 16;22(1):2363. doi: 10.1186/s12889-022-14525-7.

Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.

Global Health. 2022 Mar 18;18(1):33. doi: 10.1186/s12992-022-00822-8.

Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.

Appl Health Econ Health Policy. 2021 Jul;19(4):463-472. doi: 10.1007/s40258-021-00661-5. Epub 2021 Jul 8.

Economic evaluation of rotavirus vaccination in children of Bhutan.

Vaccine. 2020 Jul 6;38(32):5049-5059. doi: 10.1016/j.vaccine.2020.05.035. Epub 2020 Jun 7.

A review of promoting access to medicines in China - problems and recommendations.

BMC Health Serv Res. 2018 Feb 20;18(1):125. doi: 10.1186/s12913-018-2875-6.

How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.

Value Health. 2016 Dec;19(8):913-920. doi: 10.1016/j.jval.2016.04.014.

Essential medicines for universal health coverage.

Lancet. 2017 Jan 28;389(10067):403-476. doi: 10.1016/S0140-6736(16)31599-9. Epub 2016 Nov 8.

Suppr超能文献

A learning experience from price negotiations for vaccines.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译